Vasopressin antagonism in heart failure.

[1]  M. Fisher,et al.  Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine , 2004, Circulation.

[2]  K. Weber.  Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. , 2004, Journal of the American College of Cardiology.

[3]  M. Haigney,et al.  Furosemide and the progression of left ventricular dysfunction in experimental heart failure. , 2004, Journal of the American College of Cardiology.

[4]  J. Verbalis,et al.  Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia , 2004 .

[5]  C. O'connor,et al.  Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .

[6]  C. O'connor,et al.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. , 2004, Journal of the American College of Cardiology.

[7]  M. Gheorghiade,et al.  ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL , 2004 .

[8]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[9]  I. Piña,et al.  Prognostic value of hyponatremia in hospitalized patients with worsening heart failure - insights from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME - CHF) , 2003 .

[10]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[11]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[12]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[13]  A. Tuttolomondo,et al.  Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. , 2003, American heart journal.

[14]  S. Goldsmith.  Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones , 2003 .

[15]  N. Dhalla,et al.  Cardiac Remodeling and Failure , 2003, Progress in Experimental Cardiology.

[16]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[17]  J. Verbalis.  Vasopressin V2 receptor antagonists. , 2002, Journal of molecular endocrinology.

[18]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[19]  C. Johnston,et al.  Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. , 2002, Cardiovascular research.

[20]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[21]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[22]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[23]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[24]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[25]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[26]  D. Nisato,et al.  Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. , 2000, The Journal of pharmacology and experimental therapeutics.

[27]  K. Kikuchi,et al.  Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.

[28]  Y. Yamamura,et al.  Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[29]  S. Goldsmith,et al.  Vasopressin: a therapeutic target in congestive heart failure? , 1999, Journal of cardiac failure.

[30]  K. Honda,et al.  Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. , 1999, European journal of pharmacology.

[31]  H. Schunkert,et al.  Evidence for a vasopressin system in the rat heart. , 1999, Circulation research.

[32]  C. Johnston,et al.  Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. , 1998, American journal of physiology. Heart and circulatory physiology.

[33]  J. Tsukada,et al.  Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. , 1998, Cardiovascular research.

[34]  T. Takenaka,et al.  Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. , 1997, European journal of pharmacology.

[35]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[36]  Y. Kawano,et al.  Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. , 1996, Journal of cardiovascular pharmacology.

[37]  T. Saruta,et al.  Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. , 1994, The American journal of physiology.

[38]  C. Johnston,et al.  Vascular responses to vasopressin antagonists in man and rat. , 1994, Clinical science.

[39]  J. Rouleau,et al.  Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. , 1994, Journal of the American College of Cardiology.

[40]  C. S. Gal,et al.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. , 1993, The Journal of clinical investigation.

[41]  V. Gopalakrishnan,et al.  Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. , 1991, Circulation research.

[42]  H. Gavras,et al.  Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. , 1991, The Journal of laboratory and clinical medicine.

[43]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[44]  M. Creager,et al.  Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. , 1989, The Journal of clinical investigation.

[45]  D. Ausiello,et al.  Vasopressin: Cellular and Integrative Functions , 1988 .

[46]  S. Jard.  Mechanisms of action of vasopressin and vasopressin antagonists. , 1988, Kidney international. Supplement.

[47]  A. Cowley,et al.  Vasopressin and Arterial Pressure Regulation Special Lecture , 1988, Hypertension.

[48]  J. Cohn,et al.  Hemodynamic effects of infused arginine vasopressin in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[49]  C. Johnston,et al.  Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. , 1986, The Journal of clinical investigation.

[50]  K. King,et al.  Vascular role of vasopressin in the presence and absence of influence from angiotensin II or alpha-adrenergic system. , 1986, Canadian journal of physiology and pharmacology.

[51]  H. Gavras,et al.  Sequential Elimination of Pressor Mechanisms in Severe Hypertension in Humans , 1986 .

[52]  T. Ryan,et al.  Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. , 1986, Journal of the American College of Cardiology.

[53]  J. Cohn,et al.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.

[54]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[55]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[56]  R. Cody,et al.  Plasma and Platelet Vasopressin in Essential Hypertension and Congestive Heart Failure , 1983, Hypertension.

[57]  G. Riegger,et al.  Antidiuretic hormone in congestive heart failure. , 1982, The American journal of medicine.

[58]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[59]  L. Share.  Interrelations between vasopressin and the renin-angiotensin system. , 1979, Federation proceedings.

[60]  Y. Yamane.  Plasma ADH level in patients with chronic congestive heart failure. , 1968, Japanese circulation journal.